DIKUL - logo
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • Phenotypic changes in low-d...
    Carmo, Helison Rafael P.; Yoshinaga, Marcos Y.; Castillo, Alejandro Rosell; Britto Chaves-Filho, Adriano; Bonilha, Isabella; Barreto, Joaquim; Muraro, Stéfanie Primon; de Souza, Gabriela Fabiano; Davanzo, Gustavo Gastão; Perroud, Maurício W.; Lukhna, Kishal; Ntsekhe, Mpiko; Davidson, Sean; Velloso, Licio A.; Nadruz, Wilson; Carvalho, Luiz Sérgio F.; Sáinz-Jaspeado, Miguel; Farias, Alessandro S.; Proença-Módena, José Luiz; Moraes-Vieira, Pedro M.; Karathanasis, Sotirios K.; Yellon, Derek; Miyamoto, Sayuri; Remaley, Alan T.; Sposito, Andrei C.

    Molecular genetics and metabolism, 04/2023, Letnik: 138, Številka: 4
    Journal Article

    Low-density lipoprotein (LDL) plasma concentration decline is a biomarker for acute inflammatory diseases, including coronavirus disease-2019 (COVID-19). Phenotypic changes in LDL during COVID-19 may be equally related to adverse clinical outcomes. Individuals hospitalized due to COVID-19 (n = 40) were enrolled. Blood samples were collected on days 0, 2, 4, 6, and 30 (D0, D2, D4, D6, and D30). Oxidized LDL (ox-LDL), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity were measured. In a consecutive series of cases (n = 13), LDL was isolated by gradient ultracentrifugation from D0 and D6 and was quantified by lipidomic analysis. Association between clinical outcomes and LDL phenotypic changes was investigated. In the first 30 days, 42.5% of participants died due to Covid-19. The serum ox-LDL increased from D0 to D6 (p < 0.005) and decreased at D30. Moreover, individuals who had an ox-LDL increase from D0 to D6 to over the 90th percentile died. The plasma Lp-PLA2 activity also increased progressively from D0 to D30 (p < 0.005), and the change from D0 to D6 in Lp-PLA2 and ox-LDL were positively correlated (r = 0.65, p < 0.0001). An exploratory untargeted lipidomic analysis uncovered 308 individual lipids in isolated LDL particles. Paired-test analysis from D0 and D6 revealed higher concentrations of 32 lipid species during disease progression, mainly represented by lysophosphatidyl choline and phosphatidylinositol. In addition, 69 lipid species were exclusively modulated in the LDL particles from non-survivors as compared to survivors. Phenotypic changes in LDL particles are associated with disease progression and adverse clinical outcomes in COVID-19 patients and could serve as a potential prognostic biomarker. •Oxidation in the apo-B moiety of ox-LDL increases during the acute phase of COVID-19 and is related to mortality.•Plasma Lp-PLA2 activity also increases and is related to the increase in ox-LDL.•Among non-survivors, 69 species of lipids in LDL were altered during disease progression.•Altered phospholipids (e.g., phosphatidylcholine) were found exclusively in LDL from non-survivors.